

BRAMITOB®

TOBRAMYCIN

Inspiration for the lungs



Dear Respected Doctor,

Safeline Pharmaceuticals as the chosen partner to CHIESI Farmaceutici S.p.A in Southern Africa are proud to announce an alternative TIS, **Bramitob®** for the management of **cystic fibrosis**.

Safeline strives at bringing **high-quality**, **value-adding**, and **cost-effective** products to the South African market whilst improving the lives of South African patients.

Bramitob® is a **registered** advanced TIS that ameliorates CF patients' lives.

Bramitob® has a **unique particle size** that allows it to be delivered through the airways effectively. This **prevents ototoxicity** and is considered safer to use compared to the nebulization of IV solutions.

The right treatment at the right time protects patients' lung function and extends their lives¹⁻³

- Slowing the progression of lung decline is a primary aim of CF therapy by preventing or delaying chronic infection^{1,3,5}
- Chronic infection contributes to a decline in FEV1 of -2% per year⁴
- By early adulthood, most people with CF have evidence of lung function impairment⁴
- Frequency of infections changes over time with *P aeruginosa* becoming more common in adulthood⁵
- The therapeutic aim of chronic bacterial suppression can be achieved by intensive and early use of antibiotics in all age groups⁴
- When eradication therapy has failed, the diagnosis of chronic infection is made and long term inhaled antibiotic therapy (IAT) should be commenced¹

Applicant Name as Registered with MCC\SAHPRA	Nappi Code	Medicine Schedule	Medicine Propriety Name	Active Ingredients	Strength	Unit	Dosage Form	SEP
Mylan (Pty) Ltd	712097001	S4	Branded Tobramycin 300 mg/ 5 ml	Tobramycin	300 mg	5 ml	NEB	R33 694.93
Safeline Pharmaceuticals (Pty) Ltd	3003500001	S4	Bramitob Nebuliser Solution 300 mg/ 4 ml	Tobramycin	300 mg	4 ml	NEB	R27 000.00

*based on published SEP

Bramitob® is available at leading wholesalers via your hospital pharmacy as well as through South Africa's leading medical aid provider with **zero co-payment**. Should you require any further information, please do not hesitate to contact us.

Best regards,
Safeline Pharmaceuticals

References

1. Castellani et al. J Cyst Fibros. 2018;17(2):153-178.
2. Pseudomonas aeruginosa. Cystic Fibrosis Trust. 2004.
3. Antibiotic Treatment. Cystic Fibrosis Trust. 2009.
4. Elborn et al. J Cyst Fibros. 2009;8(3):211-7.
5. 2016-Patient-Registry-Annual-Data-Report, CF Foundation.

For full prescribing information and before starting your treatment, please refer to the Professional Information approved by SAHPRA.
Safeline Pharmaceuticals (Pty) Ltd, 4845 Rugby St,
Weltevreden Park, 1709. Tel: 011 288 5360. March 2023